Vor Biopharma (VOR) Total Non-Current Liabilities (2024 - 2026)

Vor Biopharma (VOR) has 3 years of Total Non-Current Liabilities data on file, last reported at $18.7 million in Q1 2026.

• Quarterly Total Non-Current Liabilities changed N/A year-over-year to $18.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.7 million (changed N/A YoY) and the FY2025 annual result came in at $27.9 million, down 39.67% from the prior year.
• Total Non-Current Liabilities slipped to $18.7 million in Q1 2026 per VOR's latest filing, from $27.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $58.8 million in Q2 2025 and bottomed at $18.7 million in Q1 2026.
• The 3-year median for Total Non-Current Liabilities is $27.9 million (2025), against an average of $34.6 million.
• Peak annual rise in Total Non-Current Liabilities reached 39.67% in 2025, while the deepest fall reached 39.67% in 2025.
• Tracing VOR's Total Non-Current Liabilities over 3 years: stood at $46.2 million in 2024, then plunged by 39.67% to $27.9 million in 2025, then tumbled by 32.92% to $18.7 million in 2026.
• Per Business Quant, the three latest VOR Total Non-Current Liabilities figures stand at $18.7 million (Q1 2026), $27.9 million (Q4 2025), and $21.6 million (Q3 2025).

Peer Comparison